{"id":1012563,"date":"2026-10-22T09:06:00","date_gmt":"2026-10-22T13:06:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/"},"modified":"2026-10-22T09:06:00","modified_gmt":"2026-10-22T13:06:00","slug":"xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/","title":{"rendered":"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026<\/b><\/p>\n<p class=\"bwalignc\"><i>Conference call and audio webcast to be held at 8:30 a.m. ET<\/i><\/p>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s third-quarter 2026 financial and operational results and business highlights.<\/p>\n<p>\nInterested parties may pre-register for the call <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F168342968&amp;esheet=54626872&amp;newsitemid=20261022621233&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=d339541626d8fa419ff2f11548a1a7f1\">here<\/a> or via the \u201cEvents\u201d section of the Investor Relations website. It is recommended that attendees register 15 minutes prior to the scheduled webcast.<\/p>\n<p>\nThe webcast, replay and other information related to the event can be accessed on the investor website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fxerispharma.com%2Finvestor-relations&amp;esheet=54626872&amp;newsitemid=20261022621233&amp;lan=en-US&amp;anchor=https%3A%2F%2Fxerispharma.com%2Finvestor-relations&amp;index=2&amp;md5=741ad4cca2a95d5fe056895724c23d47\">https:\/\/xerispharma.com\/investor-relations<\/a>.<\/p>\n<p><b>About Xeris Biopharma<\/b><\/p>\n<p>\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines for serious diseases with significant unmet medical need. Xeris has three commercially available products: Recorlev\u00ae, a cortisol synthesis inhibitor for the treatment of endogenous Cushing\u2019s syndrome; Gvoke\u00ae, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis\u00ae, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for the treatment of hypothyroidism, as well as multiple early-stage programs leveraging Xeris\u2019 technology platforms, XeriSol\u00ae and XeriJect\u00ae, for Xeris and its partners.<\/p>\n<p>\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.xerispharma.com&amp;esheet=54626872&amp;newsitemid=20261022621233&amp;lan=en-US&amp;anchor=www.xerispharma.com&amp;index=3&amp;md5=f67ec6763b5ba0ba2f4ac444ef28bd1b\">www.xerispharma.com<\/a>, or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2Fxerispharma%3Flang%3Den&amp;esheet=54626872&amp;newsitemid=20261022621233&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=f7b42f9e06927b10250bcf9bcdc26cf6\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fxeris-pharmaceuticals%2Fposts%2F%3FfeedView%3Dall&amp;esheet=54626872&amp;newsitemid=20261022621233&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=031af7e4570cd823d1597986b911f28e\">LinkedIn<\/a>, or <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fxerispharma%2F&amp;esheet=54626872&amp;newsitemid=20261022621233&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=467ae2293b1ed74361997f4507cbdb69\">Instagram<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261022621233\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261022621233\/en\/<\/a><\/span><\/p>\n<p><b>Investor and Media Contact<br \/>\n<\/b><br \/>Cristi Barnett<br \/>\n<br \/>Vice President, Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@xerispharma.com\">ir@xerispharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Illinois United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical General Health Health Clinical Trials Other Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261022621233\/en\/2942937\/3\/Xeris_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 Conference call and audio webcast to be held at 8:30 a.m. ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s third-quarter 2026 financial and operational results and business highlights. Interested &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012563","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 Conference call and audio webcast to be held at 8:30 a.m. ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s third-quarter 2026 financial and operational results and business highlights. Interested &hellip; Continue reading &quot;Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-22T13:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026\",\"datePublished\":\"2026-10-22T13:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/\"},\"wordCount\":369,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/\",\"name\":\"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-22T13:06:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/","og_locale":"en_US","og_type":"article","og_title":"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Market Newsdesk","og_description":"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 Conference call and audio webcast to be held at 8:30 a.m. ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s third-quarter 2026 financial and operational results and business highlights. Interested &hellip; Continue reading \"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-22T13:06:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026","datePublished":"2026-10-22T13:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/"},"wordCount":369,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/","name":"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-22T13:06:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022621233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012563"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012563\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}